Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH

Archives of internal medicine1 Oct 2004Cited by 202 (Europe PMC)

PMID15477438DOI10.1001/archinte.164.18.2024PepBankPUB-15477438

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, previous teriparatide reduced follow-up vertebral fracture risk by 41% versus previous placebo.
In plain wordsIn women with osteoporosis, previous teriparatide reduced subsequent vertebral fracture risk compared with previous placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFollow-up vertebral fracture risk, lower dose
Study
n: not reported in source
Comparator
Previous placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · Mean 18 months of treatment, followed by 18 months off treatmentAs given in this study (human).
Measurements
Relative fracture risk reduction
41%
20 microg versus placebo
Source sentences
Summary
During the follow-up study, the reduction in fracture risk associated with previous treatment with teriparatide, 20 and 40 microg, was 41% (P = .004) and 45% (P = .001), respectively, vs placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
This study is a follow-up to the Fracture Prevention Trial (FPT), a randomized, placebo-controlled study of postmenopausal women with osteoporosis treated with teriparatide (20 or 40 microg) once daily for a mean of 18 months.
Summary · context
Women were treated according to standard clinical practice, including elective use of osteoporosis drugs.
Summary · context
New vertebral fractures were determined by semiquantitative scoring of lateral thoracic lumbar spine radiographs 18 months after the end of the FPT.
Report a problemFND-1547743801
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, previous teriparatide reduced follow-up vertebral fracture risk by 45% versus previous placebo.
In plain wordsIn women with osteoporosis, previous higher-dose teriparatide reduced subsequent vertebral fracture risk compared with previous placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFollow-up vertebral fracture risk, higher dose
Study
n: not reported in source
Comparator
Previous placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · Mean 18 months of treatment, followed by 18 months off treatmentAs given in this study (human).
Measurements
Relative fracture risk reduction
45%
40 microg versus placebo
Source sentences
Summary
During the follow-up study, the reduction in fracture risk associated with previous treatment with teriparatide, 20 and 40 microg, was 41% (P = .004) and 45% (P = .001), respectively, vs placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
This study is a follow-up to the Fracture Prevention Trial (FPT), a randomized, placebo-controlled study of postmenopausal women with osteoporosis treated with teriparatide (20 or 40 microg) once daily for a mean of 18 months.
Summary · context
Women were treated according to standard clinical practice, including elective use of osteoporosis drugs.
Summary · context
New vertebral fractures were determined by semiquantitative scoring of lateral thoracic lumbar spine radiographs 18 months after the end of the FPT.
Report a problemFND-1547743802
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, absolute fracture risk reduction through follow-up was 13% for the lower teriparatide dose.
In plain wordsIn women with osteoporosis, the lower teriparatide dose reduced absolute fracture risk compared with placebo through follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAbsolute vertebral fracture risk reduction, lower dose
Study
n: not reported in source
Comparator
Previous placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · Mean 18 months of treatment, followed by 18 months off treatmentAs given in this study (human).
Measurements
Absolute risk reduction
13%
20 microg through follow-up
Source sentences
Summary
The absolute reduction from the FPT baseline to the 18-month follow-up visit was 13% for both doses.
4 context sentences(design, population, supporting numbers)
Summary · context
During the follow-up study, the reduction in fracture risk associated with previous treatment with teriparatide, 20 and 40 microg, was 41% (P = .004) and 45% (P = .001), respectively, vs placebo.
Summary · context
This study is a follow-up to the Fracture Prevention Trial (FPT), a randomized, placebo-controlled study of postmenopausal women with osteoporosis treated with teriparatide (20 or 40 microg) once daily for a mean of 18 months.
Summary · context
Women were treated according to standard clinical practice, including elective use of osteoporosis drugs.
Summary · context
New vertebral fractures were determined by semiquantitative scoring of lateral thoracic lumbar spine radiographs 18 months after the end of the FPT.
Report a problemFND-1547743803
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, absolute fracture risk reduction through follow-up was 13% for the higher teriparatide dose.
In plain wordsIn women with osteoporosis, the higher teriparatide dose reduced absolute fracture risk compared with placebo through follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAbsolute vertebral fracture risk reduction, higher dose
Study
n: not reported in source
Comparator
Previous placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · Mean 18 months of treatment, followed by 18 months off treatmentAs given in this study (human).
Measurements
Absolute risk reduction
13%
40 microg through follow-up
Source sentences
Summary
The absolute reduction from the FPT baseline to the 18-month follow-up visit was 13% for both doses.
4 context sentences(design, population, supporting numbers)
Summary · context
During the follow-up study, the reduction in fracture risk associated with previous treatment with teriparatide, 20 and 40 microg, was 41% (P = .004) and 45% (P = .001), respectively, vs placebo.
Summary · context
This study is a follow-up to the Fracture Prevention Trial (FPT), a randomized, placebo-controlled study of postmenopausal women with osteoporosis treated with teriparatide (20 or 40 microg) once daily for a mean of 18 months.
Summary · context
Women were treated according to standard clinical practice, including elective use of osteoporosis drugs.
Summary · context
New vertebral fractures were determined by semiquantitative scoring of lateral thoracic lumbar spine radiographs 18 months after the end of the FPT.
Report a problemFND-1547743804

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women who fractured during the trial, post hoc analysis suggested teriparatide reduced the increased risk of subsequent fracture.
In plain wordsIn women who fractured during the trial, analysis suggested previous teriparatide reduced later fracture risk compared with previous placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSubsequent fracture after an on-trial fracture
Study
n: not reported in source
Comparator
Previous placebo
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Post hoc analysis also suggests that teriparatide treatment substantially reduced the increased risk of subsequent fracture in women who sustained a fracture during the FPT (P = .05).
3 context sentences(design, population, supporting numbers)
Summary · context
This study is a follow-up to the Fracture Prevention Trial (FPT), a randomized, placebo-controlled study of postmenopausal women with osteoporosis treated with teriparatide (20 or 40 microg) once daily for a mean of 18 months.
Summary · context
Women were treated according to standard clinical practice, including elective use of osteoporosis drugs.
Summary · context
New vertebral fractures were determined by semiquantitative scoring of lateral thoracic lumbar spine radiographs 18 months after the end of the FPT.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1547743805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.